Literature DB >> 23224629

Tumor prognostic factors and the challenge of developing predictive factors.

Emma B Holliday1, Erik P Sulman.   

Abstract

Histopathologic classification has been widely used to type and grade primary brain tumors. However, the diverse behavior of primary brain tumors has made prognostic determinations based purely on clinical and histopathologic variables difficult. Recent advances in the molecular genetics of brain tumors have helped to explain the witnessed heterogeneity regarding response to treatment, time to progression, and overall survival. Additionally, there has been interest in identifying predictive factors to help direct patients to therapeutic interventions specific to their tumor and patient biology. Further identification of both prognostic and predictive biomarkers will make possible better patient stratification and individualization of treatment.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23224629     DOI: 10.1007/s11912-012-0283-3

Source DB:  PubMed          Journal:  Curr Oncol Rep        ISSN: 1523-3790            Impact factor:   5.075


  129 in total

Review 1.  The role of KIT in the management of patients with gastrointestinal stromal tumors.

Authors:  Jason L Hornick; Christopher D M Fletcher
Journal:  Hum Pathol       Date:  2007-05       Impact factor: 3.466

2.  Interfering with resistance to smoothened antagonists by inhibition of the PI3K pathway in medulloblastoma.

Authors:  Silvia Buonamici; Juliet Williams; Michael Morrissey; Anlai Wang; Ribo Guo; Anthony Vattay; Kathy Hsiao; Jing Yuan; John Green; Beatriz Ospina; Qunyan Yu; Lance Ostrom; Paul Fordjour; Dustin L Anderson; John E Monahan; Joseph F Kelleher; Stefan Peukert; Shifeng Pan; Xu Wu; Sauveur-Michel Maira; Carlos García-Echeverría; Kimberly J Briggs; D Neil Watkins; Yung-mae Yao; Christoph Lengauer; Markus Warmuth; William R Sellers; Marion Dorsch
Journal:  Sci Transl Med       Date:  2010-09-29       Impact factor: 17.956

3.  A multigene predictor of outcome in glioblastoma.

Authors:  Howard Colman; Li Zhang; Erik P Sulman; J Matthew McDonald; Nasrin Latif Shooshtari; Andreana Rivera; Sonya Popoff; Catherine L Nutt; David N Louis; J Gregory Cairncross; Mark R Gilbert; Heidi S Phillips; Minesh P Mehta; Arnab Chakravarti; Christopher E Pelloski; Krishna Bhat; Burt G Feuerstein; Robert B Jenkins; Ken Aldape
Journal:  Neuro Oncol       Date:  2009-10-20       Impact factor: 12.300

4.  Microarray analysis of pediatric ependymoma identifies a cluster of 112 candidate genes including four transcripts at 22q12.1-q13.3.

Authors:  Blanca Suarez-Merino; Mike Hubank; Tamas Revesz; William Harkness; Richard Hayward; Dominic Thompson; John L Darling; David G T Thomas; Tracy J Warr
Journal:  Neuro Oncol       Date:  2005-01       Impact factor: 12.300

5.  A prognostic gene expression signature in infratentorial ependymoma.

Authors:  Khalida Wani; Terri S Armstrong; Elizabeth Vera-Bolanos; Aditya Raghunathan; David Ellison; Richard Gilbertson; Brian Vaillant; Stewart Goldman; Roger J Packer; Maryam Fouladi; Ian Pollack; Tom Mikkelsen; Michael Prados; Antonio Omuro; Riccardo Soffietti; Alicia Ledoux; Charmaine Wilson; Lihong Long; Mark R Gilbert; Ken Aldape
Journal:  Acta Neuropathol       Date:  2012-02-10       Impact factor: 17.088

6.  Upregulation of ASCL1 and inhibition of Notch signaling pathway characterize progressive astrocytoma.

Authors:  Kumaravel Somasundaram; Sreekanth P Reddy; Katyayni Vinnakota; Ramona Britto; Madhavan Subbarayan; Sandeep Nambiar; Aparna Hebbar; Cini Samuel; Mitesh Shetty; Hari Kishore Sreepathi; Vani Santosh; Alangar Sathyaranjandas Hegde; Sridevi Hegde; Paturu Kondaiah; M R S Rao
Journal:  Oncogene       Date:  2005-10-27       Impact factor: 9.867

7.  A network model of a cooperative genetic landscape in brain tumors.

Authors:  Markus Bredel; Denise M Scholtens; Griffith R Harsh; Claudia Bredel; James P Chandler; Jaclyn J Renfrow; Ajay K Yadav; Hannes Vogel; Adrienne C Scheck; Robert Tibshirani; Branimir I Sikic
Journal:  JAMA       Date:  2009-07-15       Impact factor: 56.272

8.  Phase III trial of chemoradiotherapy for anaplastic oligodendroglioma: long-term results of RTOG 9402.

Authors:  Gregory Cairncross; Meihua Wang; Edward Shaw; Robert Jenkins; David Brachman; Jan Buckner; Karen Fink; Luis Souhami; Normand Laperriere; Walter Curran; Minesh Mehta
Journal:  J Clin Oncol       Date:  2012-10-15       Impact factor: 44.544

9.  Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.

Authors:  Roger Stupp; Monika E Hegi; Warren P Mason; Martin J van den Bent; Martin J B Taphoorn; Robert C Janzer; Samuel K Ludwin; Anouk Allgeier; Barbara Fisher; Karl Belanger; Peter Hau; Alba A Brandes; Johanna Gijtenbeek; Christine Marosi; Charles J Vecht; Karima Mokhtari; Pieter Wesseling; Salvador Villa; Elizabeth Eisenhauer; Thierry Gorlia; Michael Weller; Denis Lacombe; J Gregory Cairncross; René-Olivier Mirimanoff
Journal:  Lancet Oncol       Date:  2009-03-09       Impact factor: 41.316

10.  Epidermal growth factor receptor variant III status defines clinically distinct subtypes of glioblastoma.

Authors:  Christopher E Pelloski; Karla V Ballman; Alfred F Furth; Li Zhang; E Lin; Erik P Sulman; Krishna Bhat; J Matthew McDonald; W K Alfred Yung; Howard Colman; Shiao Y Woo; Amy B Heimberger; Dima Suki; Michael D Prados; Susan M Chang; Fred G Barker; Jan C Buckner; C David James; Kenneth Aldape
Journal:  J Clin Oncol       Date:  2007-06-01       Impact factor: 44.544

View more
  1 in total

1.  Expression level of miRNAs on chromosome 14q32.31 region correlates with tumor aggressiveness and survival of glioblastoma patients.

Authors:  Tal Shahar; Avital Granit; Daniel Zrihan; Tamar Canello; Hanna Charbit; Ofira Einstein; Uri Rozovski; Sharona Elgavish; Zvi Ram; Tali Siegal; Iris Lavon
Journal:  J Neurooncol       Date:  2016-08-29       Impact factor: 4.130

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.